Complaint Review: Instant Checkmate - Las Vegas Nevada

Bait 'n switch tactics noted by others, and mixed quality of results obtained. Some accurate, some very mixed up in identities of known people.  They did provide information as promised, most of which was accurate, but just overpriced and over-hyped.  Each report included constant grubbing for more money for another level of data or another convenience feature (pay extra to download as .pdf, for instance.)

What torqued me off was the apparent reselling of my email address and subsequent spamming.  Fortunately, I used a masked email account dedicated only to this one vendor, as well as a masked credit card, so I know this to be the only possible origin of this FLOOD of emails.  Some were blatant spoofs of false orders from, allegedly, Home Depot and Amazon.

Some these emails may actually be fraudulent: a number of false orders alledgedly from Amazon.com or Amazon Prime.  They included Amazon's Registered logo, and general appearance.  The hello was to my masked email (before the @):

" Your Account> Pending Orders

Hello,

    Your Account

           

     ORDER DATE    SHIP TO    ORDER # 002-12731#####-12731#####

May 22th, 2015        View Order Details

Estimated Delivery: May 26, 2015

Product Name: Home Energy Saver Device. Status: Ready

Product Desc: Power your home, office, appliances, etc at a drastically reduced monthly cost.

Add Amazon Discount Code -12731#####- to Your Order

     Finish Your Order

Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA. Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that have the potential to drastically reduce the risk of heart attacks when used in addition to standard treatment. France's Sanofi and its partner, Regeneron Pharmaceuticals Inc, are developing a rival drug called Praluent, and both treatments have been running neck-and-neck in the sprint to market. Neither has approval in the all-important U.S. market yet. The European Medicines Agency, on Friday, recommended approval for Repatha to be used in adult patients with hypercholesterolaemia or mixed dyslipidaemia and aged 12 years and over with homozygous familial hypercholesterolaemia. (bit.ly/1FrWu5K) Recommendations for marketing approval by its Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. Numerous trials have shown that PCSK9 inhibitors significantly lower blood levels of "bad" LDL cholesterol, but widespread use will hinge on whether the drugs are proven to prevent heart attacks, other serious heart problems. The experimental drugs are antibodies designed to target the PCSK9 protein that maintains LDL cholesterol in the bloodstream. They work differently from statins, which block the liver's production of LDL cholesterol in the first place.

stop all these http://mxvm2.afarmako.com/58194539689dref6562080conf-purchase61441686064 202 Faulk St Belle Fourche SD 57717-1225

"